Wegovy does more than suppress appetite — here's what else it's doing

You took your first dose and noticed you felt full after half a meal, that's only part of the story

A lot of people start Wegovy expecting an appetite suppressant and nothing more. The fullness after a smaller plate confirms that expectation, so the assumption settles in. It's a reasonable one to hold, and it's also incomplete.

Semaglutide binds to GLP-1 receptors, which are scattered across multiple organ systems. In the gut, it slows gastric emptying: food moves from the stomach to the small intestine more gradually, which prolongs the physical sensation of fullness. That mechanism is separate from what's happening in the brain, where semaglutide acts on appetite-regulating centres to dampen hunger signals and reduce the reward response to food. The result is that you tend to eat less, and to feel less driven to eat again quickly. Our page on how Wegovy affects appetite goes into that neural side in more depth.

But even while those two mechanisms are doing their work, semaglutide is also acting on receptors in the pancreas. It stimulates insulin release in a glucose-dependent way, meaning the effect scales with how much sugar is in your bloodstream. It also suppresses glucagon, the hormone that tells the liver to release stored glucose. Together, those actions improve blood sugar regulation, which is why the same molecule, at lower doses, has been used to treat type 2 diabetes for years. In people without diabetes, the improvements in insulin sensitivity that come with weight loss on Wegovy compound those effects further. You can read more about semaglutide's broader actions if you want the full mechanism laid out.

The cardiovascular evidence that changed how regulators think about this medicine

One of the most significant developments in the semaglutide story came from the SELECT trial, a large cardiovascular outcome study. It enrolled adults with obesity and established cardiovascular disease but without type 2 diabetes, and it was not designed as a weight-loss trial. Over an average of roughly 3.3 years, participants on semaglutide 2.4 mg had a meaningfully lower rate of major adverse cardiovascular events, including heart attack and stroke, compared with placebo. That result shifted how regulators and clinicians understood what the medicine was doing.

The MHRA and NHS now recognise a separate licensed indication for Wegovy covering reduction of cardiovascular event risk in eligible adults. At nume, prescribing is for weight management; the cardiovascular finding matters here because it illustrates that the medicine's effects extend well beyond the number on the scales. Some of the benefit probably comes from weight loss itself, and some from direct effects of semaglutide on inflammation, blood pressure, and lipid levels, the research is still unpicking that. The NHS medicines page for semaglutide covers the licensed indications clearly if you want the official summary.

There is also a newer development worth knowing about. In July 2026, the MHRA granted conditional approval for Wegovy to treat MASH, metabolically associated steatohepatitis, a form of fatty liver disease characterised by moderate-to-advanced fibrosis. This is a distinct licensed indication, separate from weight management, and it points to the same pattern: a medicine that was initially understood as a weight-loss tool turning out to have meaningful clinical effects in multiple organ systems. That finding was announced by the MHRA in July 2026.

What changes at the table, and why it's not just willpower

Something that surprises a lot of people on Wegovy is that food itself can start to feel different. Meals that were previously enjoyable can seem less appealing, or certain textures and flavours stop landing the way they did. This isn't universal, but it's common enough that it's worth naming. There's a reasonable neurological basis for it: GLP-1 receptors are present in brain regions involved in reward and motivation, and semaglutide's action there can reduce the hedonic pull of eating. Our page on why food tastes different on Wegovy explores that in more detail.

Practically, that shift means some foods become easy to leave on the plate. Fatty or rich foods, in particular, can feel less appealing, partly because gastric emptying is slower, and heavy meals sit uncomfortably. People often find themselves gravitating toward lighter options, not because they've resolved to eat more virtuously, but because their body is giving different signals. What you eat on treatment matters, though: protein adequacy, hydration, and fibre become more important when overall intake drops. The guidance on what to eat on Wegovy is a useful practical companion to understanding this.

One misconception worth letting go of gently: some people assume that because appetite is reduced, the medicine is just doing the willpower work for them, and that weight will return the moment they stop. The biology is more nuanced. The metabolic and cardiovascular effects don't switch off instantly, and the changes in eating behaviour that develop over months of treatment can persist beyond the medicine itself. That said, weight regain after stopping is real and documented, which is exactly why the decision to start, pause, or continue is a clinical one, not one to make on a forum. Speaking to a prescriber matters.

How some of these effects shape what ongoing treatment looks like

Because Wegovy acts across multiple systems, the side effect profile is broader than simple appetite reduction would predict. The most common effects are gastrointestinal (nausea, reflux, changes in bowel habit) and these typically peak after a dose increase then settle. They're a direct consequence of slowed gastric emptying and GI receptor activity, not a sign that something is going wrong.

There are rarer but more serious effects that are worth knowing about. The MHRA has highlighted acute pancreatitis as an infrequent but potentially serious risk: severe, persistent stomach pain that radiates to the back, with or without vomiting, is the warning sign that needs urgent medical attention. The Wegovy treatment overview covers the full side effect picture, and any concerns while on treatment should go to your prescriber or, if urgent, to 111 or your GP.

For those thinking about what treatment might cost, the Wegovy pricing page sets out what the private route looks like in practice. The consultation itself is free, and if a prescriber at nume confirms suitability, the price covers everything (prescription, delivery, and ongoing clinical support) with no subscription.

If you'd like to discuss whether Wegovy is right for you given everything it does, speak to our prescribers, same-day clinical review, no waiting list.